BioStem Technologies Marks Milestone in DFU Treatment Trial

BioStem Technologies Completes Enrollment in Clinical Trial

BioStem Technologies, Inc. (OTC: BSEM), a prominent name in MedTech, has successfully concluded patient enrollment for its pivotal clinical trial targeting diabetic foot ulcers (DFUs). This trial is focused on comparing the efficiency of the BioREtain® Amnion Chorion (BR-AC) allograft against the conventional standard care methods. The study promises not only to shine a light on healing efficacy but also to establish a new standard in advanced wound care treatments.

The Importance of the Clinical Trial

Conducted across various centers, the BR-AC-DFU-101 study aims to evaluate at least 60 patients suffering from non-healing DFUs. The main goal is to understand if the combination of standard care and BR-AC yields a higher chance of complete wound healing within a 12-week timeframe, when juxtaposed against the standard care alone. This trial, initiated in late 2024, has already seen an impressive enrollment of 71 patients, with results anticipated in the upcoming fourth quarter of 2025.

CEO Insights on the Trial Progress

“Advancing the clinical trials is crucial for us,” stated Jason Matuszewski, CEO and Chairman of BioStem Technologies. “I am pleased with the progress of our ongoing trials and the completed enrollment marks a significant milestone for us. As we work on additional studies targeting other types of ulcers, we remain committed to generating robust clinical data that validates our BioREtain® platform.”

Objectives and Expected Outcomes of the Trial

The clinical trial has been designed with clear primary and secondary outcome objectives. The primary objective is to establish whether treatment involving BR-AC enhances the likelihood of complete wound closure compared to standard treatment alone over the specified period.

Secondary Measures Being Analyzed

Alongside the primary outcomes, several secondary measures will also be assessed. These include:

• Differences in the rates of complete wound closure correlated with time.
• Comparing variations in wound area and volume between treatment groups.
• The required number of BR-AC applications to achieve full healing.

The Seriousness of Diabetic Foot Ulcers

Diabetic foot ulcers pose a severe health risk, impacting millions globally. Approximately 15% of individuals with diabetes experience foot ulcers, and alarmingly, a significant portion may face hospitalization due to complications. These ulcers are recognized as a leading cause of amputations in individuals with diabetes, with research indicating that up to 24% of affected individuals may eventually require such drastic measures.

Market Statistics and Economic Impact

Recent analyses indicate that around 2.2 million patients sought treatment for DFUs, with costs escalating between $9 billion and $13 billion annually in the United States alone. These figures underscore the urgent need for effective treatment options within the healthcare system to mitigate both the financial strain and health implications associated with DFUs.

About BioREtain®

BioStem’s innovative approach incorporates the proprietary BioREtain® processing method, which expertly preserves the intrinsic qualities of the perinatal tissue. This meticulous process ensures that the allografts maintain their structural integrity and natural components vital for effective wound healing, offering hope for patients battling chronic wounds.

About BioStem Technologies, Inc.

BioStem Technologies, Inc. focuses on creating advanced allografts aimed at changing lives through effective wound care. With their products adhering to stringent quality standards, their team is determined to improve patient outcomes and expand the understanding and adoption of their technologies in the medical community.

Frequently Asked Questions

What is BioStem Technologies working on currently?

BioStem is advancing multiple clinical trials to evaluate the efficacy of their BioREtain® technology in treating various types of wounds, including diabetic foot ulcers.

When are results expected from the current trial?

The company anticipates reporting topline trial results in the fourth quarter of 2025.

What is the focus of the BR-AC-DFU-101 study?

This multicenter trial focuses on assessing the effectiveness of BR-AC plus standard care in achieving wound healing among diabetic foot ulcer patients.

Why is diabetic foot ulcer treatment crucial?

DFUs can lead to severe complications, including hospitalization and amputations, making effective treatment critical for diabetic patients.

How is BioREtain® different from standard treatment methods?

BioREtain® processing preserves the natural properties of perinatal tissue, offering a potentially superior option for wound healing compared to traditional methods.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.